The most common risk factors for hyperkalemia are reduced kidney function and treatment with renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. With evidence showing the increased risk of morbidity and mortality associated with hyperkalemia caused by stopping RAASi therapy, how can we best manage potassium abnormalities and protect our patients through optimized RAASi therapy?

This panel discussion featuring Drs. George Bakris, Matthew Weir, and Faiez Zannad will highlight the latest tools for treating hyperkalemia as well as practice tips for its continued management while titrating RAASi therapy to the most effective levels.

Selection among therapies for severe asthma can be challenging, but there are 'treatable traits' clinicians can use to better predict which patients will have a favorable response.

Personalized management strategies for patients with severe asthma should consider patient history, lifestyle, triggers, comorbidities, symptoms, and patient technique, compliance, and education, as these three patient cases show.

Severe asthma is linked to significant morbidity, health care resource utilization, and long-term sequelae including airway remodeling and a greater risk of developing chronic obstructive pulmonary disease. These consequences emphasize the importance of improved identification and management of patients with severe asthma. Treatment guidelines may be confusing and it may be challenging to keep abreast of new developments. Routine assessments of lung function, frequency and severity of exacerbations, symptom control, and medication adherence are pivotal to provide necessary information for identifying and determining the most appropriate management strategy. An increased understanding of asthma pathophysiology and its correlation to disease activity has identified therapeutic targets. Biologic therapies that target T2 pathways and new supportive digital health technologies mark a new era in asthma management and treatment.

There's been an emergence of novel therapies for the treatment of severe asthma, including biologics targeting inflammatory pathways. These therapeutic options have ushered in a new era of personalized asthma management, which is why clinicians must be able to identify which patients are most likely to respond to newer biologic agents and need to be knowledgeable of the biologic and physiologic markers that form the basis for selecting a treatment.

Up to one-third of asthma cases may be misdiagnosed. Asthma symptoms overlap and can co-exist with other conditions, making it challenging to differentiate and confirm a severe asthma diagnosis. That’s why clinicians must be competent in accurately diagnosing severe asthma and distinguishing severe asthma from its mimickers.

Selection among therapies for severe asthma can be challenging, but there are 'treatable traits' clinicians can use to better predict which patients will have a favorable response.

Personalized management strategies for patients with severe asthma should consider patient history, lifestyle, triggers, comorbidities, symptoms, and patient technique, compliance, and education, as these three patient cases show.

There remains a critical unmet need for effective therapies following the recurrence of endometrial cancer. In this activity, Drs. Linda Duska and Richard Penson assess the role of immunotherapy and targeted therapies in managing advanced endometrial cancers, as well as the importance of evaluating the microsatellite and mismatch repair biomarker status of recurrent and metastatic endometrial cancer.

Since the release of this activity, the FDA has approved the use of dostarlimab for the treatment of patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR, as determined by an FDA-approved test. Visit the FDA statement dated 22 April 2021 to learn more.

Clinicians must be knowledgeable of the inflammatory, immunologic, and pathobiologic features leading to severe asthma. Clinicians must also have knowledge of severe asthma phenotypes and the implications for treating patients.

Severe asthma is a heterogenous disease, and patients present with a variety of clinical histories, physiologic changes (beyond changes in forced expiratory volume in one second), and airway inflammation. That’s why Dr. Sandra Adams is joined by Dr. Linda Rogers, Clinical Director of the Asthma Program at the Icahn School of Medicine at Mount Sinai, to discuss how we can better differentiate difficult-to-control and severe or refractory types of asthma.

Recent advances in asthma therapy have included several new biologic agents that modify Th2-inflammatory pathways. Treatment guidelines have provided a framework for the treatment of patients with Th2-mediated allergic asthma. However, approximately half of asthmatic patients do not fall within the Th2 inflammatory paradigm. Cinicians must be knowledgeable of treatment options and the role of potential novel therapies for this subgroup of patients.